Wuhan YZY Biopharma (2496 HK)

Wuhan YZY Biopharma Co., Ltd. is a biotechnology company that develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company's pipeline includes product candidates for various solid tumors, ocular neovascularization-related diseases, hemophilia, and inflammatory bowel diseases, utilizing platforms like Y-BODY®, Check-Body, and Nano-Ybody®. It was founded in 2010 and is headquartered in Wuhan, China.